Abstract:11034 Background: Imatinib is the standard treatment for patients of Gastrointestinal Stromal Tumors (GISTs), but the intra- and inter-variability of imatinib plasma trough concentration (Cmin) are significant. Few studies investigated the association between Cmin and adverse reaction in Chinese GIST patients. The distribution of imatinib Cmin in different doses and the correlation of imatinib Cmin with adverse reaction in Chinese GIST patients from a high-volume center were evaluated. Methods: From 1 Jul 2017 to 31 Dec 2018, a total of 400 patients who were under imatinib treatment were prospectively studied. All patients’ informed consents were obtained. Steady state plasma samples were obtained from patients at least administrating 1 month treatment who were taking imatinib 100 to 800 mg/d, with continuous similar timing of daily dosage for more than 14 days. The adverse reaction was recorded during regular follow-up at out-patient clinic, and blood sample was collected 22±2 hours to the next dosage of imatinib. Liquid chromatography tandem mass spectrometry was applied to determine the concentration. Adverse reaction grades were referred to CTCAE v4.0. Results: A total of 368 patients who followed the same dose of imatinib with good compliance, and having at least 2 times of tests were investigated. The imatinib Cmin was 384±53 ng/mL, 776±337 ng/mL, 986±327 ng/mL, 1078±498 ng/mL, 1309±712 ng/mL, 1620±469 ng/mL, 2117±597 ng/mL and 3844±987 ng/mL in patients who were administrated with 100 mg/d (n = 3), 200 mg/d (n = 15), 250 mg/d (n = 5), 300 mg/d (n = 80), 400 mg/d (n = 235), 500 mg/d (n = 3), 600 mg/d (n = 22) and 800 mg/d (n = 5), respectively. In correlation analysis, imatinib Cmin was significantly correlated with periorbital and limbs edema (p < 0.01), anemia (p < 0.01) and rush (p < 0.01), correlated with diarrhea and conjunctival hemorrhage but not significant. Much higher Cmin was observed in severe adverse reaction (≥ grade 3) of periorbital and limbs edema and rash. There was no correlation between Cmin with leukopenia, nausea, vomiting, muscle cramp or hepatobiliary disorders. Conclusions: In Chinese GIST patients, imatinib Cmin at steady state was seems higher than Western populations previous reported, especially in higher doses (≥600 mg/d). Imatinib Cmin was correlated with anemia, periorbital and limbs edema, diarrhea and conjunctival hemorrhage, suggesting that imatinib Cmin monitor might be considered when patients were subjected to severe adverse reactions which were caused by excessive imatinib plasma concentration.

Untargeted metabolomics analysis reveals the potential mechanism of imatinib-induced skin rash in patients with gastrointestinal stromal tumor

Preliminary study of immunology mechanism of erlotinib-induced skin rash

Clinical Analysis of 76 Cases of Erlotinib-Induced Skin Rash in the Treatment of Non-Small Cell Lung Cancer

Establishment and application of a predictive model for gefitinib-induced severe rash based on pharmacometabolomic profiling and polymorphisms of transporters in non-small cell lung cancer

Correlation of Gefitinib and Its Metabolites with Gefitinib Induced Rash in Patients with Non-Small Cell Lung Cancer (NSCLC).

Sensitive Metabolites and Single Nuclear Polymorphisms of OCT1 on Imatinib Meyslate in Patients with Gastrointestinal Stromal Tumors (GISTs)

Therapeutic drug monitoring‐based dose optimization for imatinib‐associated serious cutaneous reactions in a patient with gastrointestinal stromal tumours: A case report

Lichenoid Drug Eruption Caused by Imatinib Mesylate in a Chinese Patient with Gastrointestinal Stromal Tumor.

Efficacy and safety of adjuvant post-surgical therapy with imatinib in gastrointestinal stromal tumor patients with high risk of recurrence: interim analysis from a multicenter prospective clinical trial]

A Phase Ii Study of Imatinib for Advanced Melanoma Patients with Kit Aberrations

Topical JAK inhibition ameliorates EGFR inhibitor–induced rash in rodents and humans

Impact of systemic steroids on the efficacy of first line imatinib treatment of patients with advanced gastrointestinal stromal tumors (GISTs)

Skin Rash Could Predict The Response To Egfr Tyrosine Kinase Inhibitor And The Prognosis For Patients With Non-Small Cell Lung Cancer: A Systematic Review And Meta-Analysis

Impact Of Pharmacogenomics On Imatinib Toxicity In Gastrointestinal Stromal Tumors.

Correlations between imatinib plasma trough concentration and adverse reactions in Chinese patients with gastrointestinal stromal tumors.

Imatinib Mesylate in the Treatment of Advanced Gastrointestinal Stromal Tumors

Comparison of Plasma Metabolites From Patients With Non-Small Cell Lung Cancer by Erlotinib Treatment and Skin Rash

Efficacy and safety of imatinib on treatment for patients with advanced gastrointestinal stromal tumors

Clinical Analysis of Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor

Deciphering the tumor immune microenvironment of imatinib-resistance in advanced gastrointestinal stromal tumors at single-cell resolution

Correlation of Imatinib Plasma Trough Concentrations with Adverse Reaction in Chinese Gastrointestinal Stromal Tumors Patients.